Expert Analysis

Advances in HCV Management Strategies With Approved Agents

Source: CCO Independent Conference Coverage of the 2007 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Advances in HCV Management Strategies With Approved Agents

Faculty:

Raymond T. Chung, MD
Mitchell L. Shiffman, MD
Mark S. Sulkowski, MD

CME CREDIT INFORMATION

Release Date: 12/20/07

Expiration Date: 12/19/08

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.5 Nursing CE credits

Pharmacists: 1.5 contact hours (0.15 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss recent data on the use of agents approved by the US Food and Drug Administration for the treatment of patients with chronic hepatitis C and strategies for managing their adverse effects
Summarize new insights into factors associated with response and nonresponse to treatment for chronic hepatitis C
Describe the latest findings on retreatment strategies for patients with hepatitis C virus with previous nonresponse to interferon and ribavirin-based regimens

Topics covered include:

Baseline Predictors of Response in Patients Infected With the Same HCV Strain
Predicting Sustained Virologic Response in HCV Genotype 2/3-Infected Patients Without a Rapid Virologic Response
Predictors of Rapid Virologic Response in Patients With HCV Genotype 1 Infection
Predictive Value of On-Treatment Responses for Sustained Virologic Response
Influence of Polymerase Chain Reaction Assay Sensitivity on Response-Guided Therapy
Interim Analysis of High-Dose Peginterferon alfa-2a Induction Therapy in Treatment-Naive Patients
Benefit of Longer Duration of Therapy for HCV Genotype 1 Patients With an Incomplete EVR
Improving Adherence to Treatment Through Patient Education
Weight-Based Peginterferon Alfa-2b and Weight-Based Ribavirin for HCV
Impact of Eliminating Ribavirin in Genotype 2/3–Infected Patients Who Achieve RVR
Retreatment Strategies for Previous Peginterferon alfa/Ribavirin Nonresponders
Maintenance Peginterferon for Previous Peginterferon/Ribavirin Nonresponders

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.